Revealed Versus Concealed Cerebroplacental Ratio


The purpose of this study is to evaluate the role of an integrated strategy at selecting fetuses for delivery at term based on a combination of fetal biometry and cerebroplacental ratio (CPR) to reduce stillbirth rate and adverse perinatal outcome.

Full Title of Study: “Revealed Versus Concealed Criteria for Placental Insufficiency in Unselected Obstetric Population in Late Pregnancy: a Multicenter Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2018

Detailed Description

This is a multicenter, open-label randomized trial with groups in parallel. Singleton pregnancies are recruited after routine second trimester scan (19+0 to 22+6 weeks of gestation) and randomly allocated at that moment to revealed or concealed strategy. A routine scan will be booked at 36-37 weeks. For a reduction of the stillbirth rate of 3‰ (from 5‰ to 2‰), assuming a type I error of 5% and aiming for a power of 80% a total of 11,582 subjects (5791 per arm) were projected. The participating centers sum up 12,000 deliveries a year. It is not possible to blind participants, obstetricians, or outcome assessors to the study group.

General hypothesis: A proportion of fetuses with "normal" growth as per current standards have placental insufficiency and restriction of their growth potential. These fetuses exhibit biophysical changes expressed by abnormal cerebroplacental ratio. A combination of this marker with fetal biometry for the detection of fetuses affected by fetal growth restriction could identify a group of babies on which labor induction once term is reached may prevent the occurrence of adverse outcomes.

Specific hypothesis

- The cerebroplacental ratio has predictive value in late pregnancy for placental insufficiency.

- The cerebroplacental ratio could improve the effectiveness of late pregnancy screening for the prediction placental insufficiency-related complications.


  • Other: Revealment
    • Cerebroplacental ratio revealment

Arms, Groups and Cohorts

  • No Intervention: Concealment
    • Cerebroplacental ratio measurement at 37 weeks of pregnancy only taken into account if estimated fetal weight <p10
  • Other: Revealment
    • Cerebroplacental ratio measurement at 37weeks and labor induction in case of cerebroplacental ratio <p5

Clinical Trial Outcome Measures

Primary Measures

  • Stillbirth
    • Time Frame: between 37 and 42 weeks of pregnancy

Secondary Measures

  • Adverse perinatal outcome
    • Time Frame: Up to 28 days after delivery
  • Fetal Growth Restriction Detection
    • Time Frame: 3 years

Participating in This Clinical Trial

Inclusion Criteria

  • Viable singleton non-malformed fetus
  • Available first-trimester US dating
  • Maternal age at recruitment ≥18 years
  • No adverse medical or obstetrical history at booking
  • Capacity to give informed consent

Exclusion Criteria

  • Abnormal karyotype
  • Structural abnormalities
  • Congenital infections

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Hospital Clinic of Barcelona
  • Provider of Information About this Clinical Study
    • Principal Investigator: Francesc Figueras, Obstetrics Department Head Hospital Clinic Barcelona – Hospital Clinic of Barcelona
  • Overall Official(s)
    • Eduard Gratacos, PhD, Study Chair, Hospital Clinic
  • Overall Contact(s)
    • Francesc Figueras, PhD, 0034932279946,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.